Search

Your search keyword '"Caimi, Paolo F"' showing total 687 results

Search Constraints

Start Over You searched for: Author "Caimi, Paolo F" Remove constraint Author: "Caimi, Paolo F"
687 results on '"Caimi, Paolo F"'

Search Results

51. Postibrutinib Relapse Outcomes for Patients with Marginal Zone Lymphoma

54. Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

56. Contributors

59. A population level analysis of second hematological malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma survivors in the era of targeted therapies.

60. Evaluation of Major Adverse Cardiac Events (MACE) and Arrhythmias in Patients with Large B-Cell Lymphoma Undergoing Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Utility of Baseline Cardiac Biomarkers

62. Postibrutinib relapse outcomes for patients with marginal zone lymphoma

63. A Multicenter Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia

67. Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411

68. Siltuximab for First-Line Treatment of Cytokine Release Syndrome: A Response to the National Shortage of Tocilizumab

70. Assessment of Major Adverse Cardiac Events (MACE) and Arrhythmias in Patients with Large B-Cell Lymphoma Undergoing Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Impact of Baseline Cardiac Biomarkers

71. Multicenter Phase I Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia

72. CD19 Expression by IHC Alone Is Not a Predictor of Response to Loncastuximab Tesirine: Results from the LOTIS-2 Clinical Trial and Quantitative Systems Pharmacology Modeling

74. Circulating Tumor DNA Correlation with Lymphoma Response and Survival Outcomes at Multiple Time Points of Anti - CD19 CAR T Cell Therapy

75. Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

76. Outcomes of Relapsed Refractory Double Hit Lymphoma: A Multicenter Observational Cohort

77. Metabolic Tumor Volume Predicts Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Trial

78. Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study

83. Assessment of Pretreatment and Posttreatment Evolution of Neurofilament Light Chain Levels in Patients Who Develop Immune Effector Cell–Associated Neurotoxicity Syndrome

84. Lenalidomide maintenance following high‐dose therapy and autologous haematopoietic stem cell transplantation in chemo‐resistant or high‐risk non‐Hodgkin lymphoma: A phase I/II study.

85. Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study

86. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes.

87. Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States.

91. Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin Lymphoma

92. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes

93. The Association of Pre-Transplant Adiposity with Autologous Hematopoietic Stem Cell Transplantation Outcomes in Lymphoma

94. Validation of Pre-Treatment Modified Easix Score As a Predictor of Cytokine Release Syndrome Related to Anti CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

95. Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomes

97. Sequential Single Cell Transcriptional and Protein Marker Profiling Reveals Tigit As a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin's Lymphoma

98. TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data

99. The Anti-CD19 Antibody-Drug Conjugate Loncastuximab Tesirine Achieved Responses in Patients with Diffuse Large B-Cell Lymphoma Who Relapsed after Anti-CD19 CAR T-Cell Therapy

100. S1918: A Phase II/III Randomized Study of R-Minichop with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements

Catalog

Books, media, physical & digital resources